A lipopeptide agonist of TLR2/TLR6
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

FSL-1 (trifluoroacetate salt)

Item No. 24220

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-α-aspartyl-L-prolyl-L-lysyl-L-histidyl-L-prolyl-L-lysyl-L-seryl-L-phenylalanine, trifluoroacetate salt
Molecular Formula
C84H140N14O18S • XCF3COOH
Formula Weight
1666.2
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
Water: 2 mg/ml
SMILES
O=C(O)[C@@H](NC([C@H](CO)NC([C@H](CCCCN)NC([C@H]1N(C([C@@H](NC([C@H](CCCCN)NC([C@@H]2CCCN2C([C@H](CC(O)=O)NC(CNC([C@@H](N)CSCC(OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O)=O)=O)=O)=O)=O)CC3=CN=CN3)=O)CCC1)=O)=O)=O)CC4=CC=CC=C4.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C84H140N14O18S.C2HF3O2/c1-3-5-7-9-11-13-15-17-19-21-23-25-30-44-74(103)115-56-62(116-75(104)45-31-26-24-22-20-18-16-14-12-10-8-6-4-2)57-117-58-63(87)76(105)89-54-72(100)91-67(52-73(101)102)83(112)98-49-37-43-71(98)81(110)92-64(40-32-34-46-85)77(106)94-66(51-61-53-88-59-90-61)82(111)97-48-36-42-70(97)80(109)93-65(41-33-35-47-86)78(107)96-69(55-99)79(108)95-68(84(113)114)50-60-38-28-27-29-39-60;3-2(4,5)1(6)7/h27-29,38-39,53,59,62-71,99H,3-26,30-37,40-52,54-58,85-87H2,1-2H3,(H,88,90)(H,89,105)(H,91,100)(H,92,110)(H,93,109)(H,94,106)(H,95,108)(H,96,107)(H,101,102)(H,113,114);(H,6,7)/t62?,63-,64-,65-,66-,67-,68-,69-,70-,71-;/m0./s1
InChi Key
UANJOAKJMWZEBV-ALAVPRNSSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $107

    Add

    1 mg

    $203

    Add

    5 mg

    $688

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    FSL-1 is a synthetic lipopeptide agonist of toll-like receptor 2 (TLR2) and TLR6 heterodimers (TLR2/TLR6).1,2 In HEK293 cells transfected with human TLR2 and TLR6 but not TLR6 alone, FSL-1 increases NF-κB activity by 4- and 8-fold when used at concentrations of 0.1 and 1 nM, respectively.1 It induces the expression of the cytokines CCL20, IL-8, IL-1β, and TNF-α in human monocytic THP-1 cells and, to a lesser extent, in TLR10 knockdown cells when used at a concentration of 100 ng/ml.3 FSL-1 (0.5-50 μg/ml), in combination with IFN-γ, dose-dependently increases the percentage of DM13 and VMM1 melanoma cells expressing the chemokine CXCL10 with a maximal increase of approximately 50%.4 In rats, FSL-1 (100 μg/kg, i.p.) induces fever and increases plasma levels of IL-6 and TNF-α by greater than 90-fold.5 FSL-1 (10-1,000 μg/kg, i.p.) also dose-dependently reduces home cage locomotor activity and both food and water consumption with maximal reductions of ten grams per 12 hours.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Okusawa, T., Fujita, M., Nakamura, J., et al. Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6. Infect. Immun. 72(3), 1657-1665 (2004).

    2. Farhat, K., Riekenberg, S., Heine, H., et al. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J. Leukoc. Biol. 83(3), 692-701 (2008).

    3. Le, H.V., and Kim, J.Y. Stable Toll-Like Receptor 10 Knockdown in THP-1 Cells Reduces TLR-Ligand-Induced Proinflammatory Cytokine Expression. Int. J. Mol. Sci. 17(6), E859 (2016).

    4. Mauldin, I.S., Wang, E., Deacon, D.H., et al. TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. Int. J. Cancer 137(6), 1386-1396 (2015).

    5. Hübschle, T., Mütze, J., Mühlradt, P.F., et al. Pyrexia, anorexia, adipsia, and depressed motor activity in rats during systemic inflammation induced by the Toll-like receptors-2 and -6 agonists MALP-2 and FSL-1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290(1), R180-R187 (2006).